New Therapeutic Strategies Targeting Myeloid Malignancies

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify therapeutic targets and/or therapeutic assets that target Myeloid Malignancies, specifically Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN).

Our client is seeking to identify therapeutics and associated research focused on the treatment of Myeloid Malignancies, specifically, the identification and assessment of therapeutic targets and pathways that can be leveraged to develop the next generation of cancer therapeutics. All drug modalities are of interest to this campaign.

Specific pathways in Myeloid Malignancies that are of interest

- Pro-apoptotic pathways
- Epigenetic targets
- Differentiation of myeloid malignant cells
- Tumour specific membrane targets not expressed on healthy cells, including haematopoietic stem cells and other haematological progenitors
- Regulators of splicing

Developmental Stages of Interest

- Opportunities at the basic research phase through to clinical phase II is within scope
- Opportunities with some form of validation are of highest interest e.g. in vivo and/or in vitro data

Out of Scope

- Chronic Myeloid Leukaemia

Submission Information & Potential Collaborations for Academics

- Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information
- Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Our client has significant programs available to help with the translational aspect of academic research, with example outcomes include licensing assets, project/PhD funding, and research collaborations

Opportunities sought

- Spinout companies
- Research projects
- Centres of excellence
- Academics and expertise
- Technologies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 25th October 2021 - 10:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

© 2021 IN-PART All rights reserved